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Abstract
The aim of this research was to test a novel in-vivo brain MRI analysis method that
could be used in clinical cohorts to investigate cortical architecture changes in
patients with Alzheimer's Disease (AD). Three cohorts of patients with probable AD
and healthy volunteers were used to assess the results of the method. The first group
was used as the “Discovery” cohort, the second as the “Test” cohort and the last
“ATN” (Amyloid, Tau, Neurodegeneration) cohort was used to test the method in an
ADNI 3 cohort, comparing to amyloid and Tau PET. The method can detect altered
quality of cortical grey matter in AD patients, providing an additional tool to assess
AD, distinguishing between these and healthy controls with an accuracy range
between good and excellent. These new measurements could be used within the
“ATN” framework as an index of cortical microstructure quality and a marker of Neu-
rodegeneration. Further development may aid diagnosis, patient selection, and quan-
tification of the “Neurodegeneration” component in response to therapies in clinical
trials.
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1 | INTRODUCTION
Approximately 50% of dementia sufferers are thought to be
undiagnosed, particularly in the early stages of disease. Early
detection of Alzheimer's Disease (AD) also presents a challenge for
patient inclusion in drug trials, which may have contributed to trial
failures costing pharmaceutical companies billions of dollars. New
ways to quantify AD are needed to add to the repertoire of exis-
ting methods if we are to overcome these challenges. The newly
proposed Alzheimer's classification framework suggests a descrip-
tion based on a patient's biomarker profile (Jack Jr et al., 2018). In
Abbreviations: AD, Alzheimer's Disease; AngleR, angle between the principal diffusion
direction and the minicolumn direction within the cortex; GM, grey matter; MD, mean
diffusivity; ParlPD, the component of the principal diffusion vector that was parallel to the
minicolumn direction within the cortex; PerpPD, the component of the principal diffusion
vector perpendicular to the minicolumn direction within the cortex.
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this “ATN” framework (“A” for amyloid deposition, “T” for tau
levels, and “N” for neurodegeneration) AD forms a continuum in
which the extreme points are represented by A−T−N−cognitively
unimpaired subjects, and A+ T+ N+ subjects with dementia. The
present study focused on change in the underlying neural architec-
ture responsible for cognitive function as a potential “N”
biomarker.
In addition to cell loss and synapse loss, the vertical cellular
micro-circuits, known as minicolumns, which constitute the funda-
mental structure throughout the cerebral cortex, are altered in a
graded manner during ageing, mild cognitive impairment (MCI),
and AD (Chance et al., 2011). The microscopic disruption of
columnar architecture correlates with plaque load and cognitive
decline (van Veluw et al., 2012). A novel analysis method using Dif-
fusion Tensor MRI to measure correlates of these cortical micro-
structural changes was previously validated against postmortem
histology (McKavanagh et al., 2019) and tested in in-vivo cohorts
(Dickstein et al., 2020; Torso, Ahmed, et al., 2020; Torso, Bozzali,
et al., 2020).
The present study aimed to provide the first preliminary in-vivo
validation of these neuroimaging measurements in AD cohorts to
demonstrate that they are sensitive to dementia-related microstruc-
tural changes. This analysis method is complementary to other “N”
biomarkers and requires only conventional MRI scanners, standard
diffusion protocols, and no contrast agents. It is, therefore, poten-
tially applicable to a variety of acquisition environments, including
clinical.
This study aimed to test: (1) if the cortical diffusivity analysis pro-
vided generalizable in vivo measures of cortical grey matter diffusivity;
(2) if the cortical diffusivity analysis can discriminate between groups;
(3) how the discriminative power of the method compared with other
clinical biomarkers (Cortical grey matter volume, AV45, and AV1451
PET for amyloid and tau).
2 | METHODS
2.1 | Study participants
A total of 78 individuals with probable AD and 71 healthy elderly con-
trols (HC) from three different cohorts were included in the study.
The first cohort (24 AD, 23 HC) was an existing dataset recruited
in Oxford (UK) (Zamboni et al., 2013) and was used as a “Discovery
cohort” to explore the in-vivo validity of a novel method of cortical
diffusivity analysis (Table 1).
The second cohort (29 AD, 23 HC) was an existing dataset rec-
ruited in Rome (Italy) (Giulietti et al., 2018) and was used as a “Test
cohort” to test repeatability of the method in an independent sample
(Table 1).
All subjects underwent extended clinical and neuropsychological
assessments, which were centre specific (Giulietti et al., 2018; Zam-
boni et al., 2013), but included the Mini Mental State Examination














































































































































































































































































































































































































































































































































































































































































2 TORSO ET AL.
Rating scale (CDR) (Hughes, Berg, Danziger, Coben, & Martin, 1982).
Inclusion criteria for healthy elderly controls were: MMSE score
between 24 and 30, a CDR of 0, no psychopharmacological treatment,
no subjective memory complaints, absence of psychiatric and neuro-
logical conditions, absence of history of cancer, non-MCI, and non-
demented.
A third cohort (25 AD, 25 HC) was selected from the Alzheimer's
Disease Neuroimaging Initiative 3 database (ADNI 3). This is the most
up-to-date ADNI cohort with a consistent acquisition protocol. All AD
subjects available at the time of the study design were included if they
had biomarker data enabling them to be classified according to the
ATN framework (Jack Jr et al., 2018) and had MRI data acquired using
consistent ADNI3 protocols. A matched HC group was selected. All
subjects of this cohort were characterized based on the ATN frame-
work, using UC Berkeley AV45 Florbetapir and AV1451 Flortaucipir
PET values. The AV45 PET standard uptake value ratio (SUVR) (whole
cerebellum reference region) values were used to assess amyloid
deposition: T1 scans for each subject were segmented and parcellated
with Freesurfer to define cortical grey matter regions of interest (fron-
tal, anterior/posterior cingulate, lateral parietal, and lateral temporal)
that make up a summary cortical ROI. The AV45 Florbetapir SUVR
values were calculated by averaging across the four cortical regions
and dividing this cortical summary ROI by the whole cerebellum refer-
ence region (cutoff of 1.11; Joshi et al., 2012). TheAV1451 PET SUVR
values were used to assess tau lesions. The SUVR values were calcu-
lated by dividing the region of interest (Braak stage V composite
value) by a reference region (cerebellar GM, cutoff 1.33; Jack Jr
et al., 2017).
The clinical diagnosis was given according to the National
Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer''s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria (McKhann et al., 2011). This cohort was
used as the “ATN” cohort to test the validity of the novel cortical
diffusion metrics and their potential role as “N” biomarkers com-
pared with other “A” and “T” biomarkers. To better describe the
cohort, APOE genotype was added. Note that, the tests of diag-
nostic accuracy for the ATN cohort (below) used the subject clini-
cal diagnosis as the criteria for diagnostic grouping. The ATN
markers were only used as a framework for reference, but did not
form part of subject categorization for classification testing within
this study.
2.2 | Structural MRI analyses
All participants had undergone MRI scanning to acquire T1 Structural
and Diffusion weighted scans.
The 3D T1-weighted image was segmented using FreeSurfer
v6.0 (http://surfer.nmr.mgh.harvard.edu/) to compute GM fraction
(GM fr), Bilateral Hippocampal fraction (Hipp Bil fr), and White
Matter Hypointensities fraction (WMHs fr) (see Supplementary
material).
2.3 | DTI analysis
DTI preprocessing was performed using FSL tools (http://www.fmrib.
ox.ac.uk/fsl/) (see Supporting Information).
To control for the effect of head motion (Baum et al., 2018) in
DTI maps, a displacement index generated using an in-house script
was calculated (see Supporting Information). This value was used as a
covariate in the General Linear Model (GLM) multivariate analysis.
2.4 | Cortical diffusivity analysis
The automatic cortical diffusivity analysis consisted of several differ-
ent stages performed using a proprietary software tool (see
Supporting Information and McKavanagh et al., 2019). In summary,
the tool generates cortical profiles, that is, lines estimating the colum-
nar axis within the cerebral cortex. Values for the diffusion tensor
derived metrics were averaged along the cortical profiles, across the
whole cortical grey matter to provide a global, summary value for each
one. The metrics calculated were mean diffusivity (MD) and three
measures relating to the principal diffusion component, namely: the
angle between the radial minicolumn direction within the cortical GM
and the principal diffusion direction (AngleR, θrad); the principal diffu-
sion component projected onto the plane perpendicular to the radial
minicolumn direction (PerpPD, D1,⊥ [×10−3 mm2/s]), and the principal
diffusion component projected onto, and therefore parallel with, the
radial minicolumn direction (ParlPD, D1,k [×10−3 mm2/s]).
Readers may be familiar with MD as a measure of the total diffu-
sion occurring in a voxel. It is calculated by finding an average of the
three eigenvalues (i.e., [L1 + L2 + L3]/3). In the present study, addi-
tional measures were calculated as described in US20180143282A1:
The perpendicular diffusivity was determined by multiplying the main
eigenvector (V1) by the value of its corresponding eigenvalue (L1),
then resolving this into its components. The value of the component
perpendicular to the radial minicolumn direction across the cortex
was the perpendicular diffusivity. Radial or parallel diffusivity was the
component of the diffusion occurring in the principal diffusion direc-
tion that was parallel to the radial minicolumn direction across the
cortex. The angle of columnar deviation, also called AngleR, was the
difference between the radial minicolumn direction across the cortex,
and the direction of the main eigenvector (V1), expressed as an angle.
The direction, CRadial, was derived, spanning the cortical ribbon
between the pial and white matter boundary surfaces. Over 100,000
approximately evenly-spaced points on the white matter surface were
taken, and cortical profiles were propagated through the cortical layers
replicating the histological principles of radial minicolumns (Rakic, 1995),
aiming to minimize the crossings of profiles, and reflecting the inside-out
migration of cells along radial glial guidelines toward corresponding points
representative of Cajal–Retzius cells at the pial surface. The cortical pro-
files were then selected for inclusion, taking into account features of cor-
tical geometry that are known to influence or correlate with minicolumn
width, shape and cell density, including cortical thickness and curvature.
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All the cortical values were averaged to reduce the influence of
noise in the DTI scans, effectively smoothing the data, and ensuring
only directionality with some local coherence would dominate, there-
fore guarding against the influence of random deflections from the
minicolumn direction. Each of the three novel metrics, AngleR, Per-
pPD, and ParlPD, was based on an average from the whole cortex. As
with other widely used metrics, such as whole brain volume (which
does not discriminate between the many tissue compartments and
sub-structures), a summary value for each subject has the advantage
that it provides a good overview of group differences without the
complications of sub-region sampling, requiring multiple covariates
and multiple testing corrections.
2.5 | Validity
To test the validity of the method, the study design enabled the
assessment of several different validity requirements:
i. Repeatability: investigated as intrascanner variation, that is, the
degree of variation produced by running the cortical diffusivity
analysis on the same subjects (six controls) at two different time
points, baseline and follow-up after a three-month interval,
acquired on the same scanner.
ii. Reliability: investigated as Interscanner variation, that is the
degree of variation produced by running the cortical diffusivity
analysis on similar cohorts, acquired on different scanners. To do
that, the cortical diffusivity analysis was run on the Discovery,
Test and ADNI3 cohorts.
iii. Construct validity: the degree to which the cortical diffusivity
analysis measured what it claimed to be measuring, was
assessed using correlations between cortical diffusivity analysis
measures and other common indices of brain structural degen-
eration (GM fr, Hipp bil fr, and WMHs fr) and global cognitive
status (MMSE).
iv. Concurrent validity: the relationship between the measures
obtained through the novel method and the standard disease
measures included in the ATN framework (AV45 PET SUVR com-
posite values and the AV1451 PET SUVR values), was assessed
in the ATN cohort.
2.6 | Diagnostic accuracy
To test the diagnostic accuracy of the cortical diffusivity analysis mea-
sures, different indices were estimated. The group discrimination capa-
bility (diagnostic group: HC vs. AD) of cortical diffusivity measures was
investigated using Receiver Operating Characteristics (ROC) curve anal-
ysis and compared with a conventional diffusion measure (MD) and
GM_fr (considered as a measure of atrophy and one of the main mea-
sures of neurodegeneration). As is well known, hippocampal atrophy is
a sub-region value and is one of the main criteria to define AD diagno-
sis and therefore formed part of the group classification criteria, so it
was not used in the discrimination capability comparison.
We considered as the “best discriminator” the feature with the
highest area under the ROC curve (AUC). Finally, to summarize the predic-
tive value of each measurement, the accuracy (ACC), sensitivity (SENS),
specificity (SPEC), positive likelihood ratio (LR+), negative likelihood ratio
(LR−), Youden's J statistic, positive predictive value (PPV), and negative
predictive value (NPV) were computed at the best point along the ROC
curve for each measurement. We defined the best point as the one with
the highest value obtained by averaging sensitivity and 1 − specificity.
2.7 | Statistical analysis
Data were analyzed using IBM SPSS Statistics version 25 (SPSS, Chi-
cago, IL).
The multivariate General Linear Model (GLM) of SPSS was used
to compare between-group differences in cortical diffusivity measures
TABLE 2 Brain volumetrics
Dataset Diagnosis Grey matter fraction GM fr Hippocampal fraction Hip fr WMHs fraction WMHs fr
Discovery cohort (Oxford) HC
n = 23
0.265 ± 0.037# 0.00465 ± 0.00051# 0.00391 ± 0.0060
AD
n = 24
0.221 ± 0.024a 0.00340 ± 0.00072a 0.00517 ± 0.0057a
Test cohort (Rome) HC
n = 23
0.267 ± 0.035# 0.00470 ± 0.00081# 0.00248 ± 0.0015#
AD
n = 29
0.222 ± 0.025a 0.00320 ± 0.00079a 0.00409 ± 0.0024a
ATN cohort (ADNI 3) HC
n = 25
0.292 ± 0.018# 0.00502 ± 0.00060# 0.00220 ± 0.0024
AD
n = 25
0.267 ± 0.023a 0.00373 ± 0.00058a 0.00373 ± 0.0039a
Note: The table shows the mean (SD) of Grey Matter fraction. Hippocampal Bil fraction and WMHs fraction. p < .05 after Bonferroni's Correction for
multiple comparisons (statistical threshold = p < .016 [0.05/3]). “#” denotes significant difference.
Abbreviations: AD, Alzheimer's Disease; HC, healthy controls.
at-test.
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in the cohorts, using group membership as a fixed factor and head
movement, subject age, and scanner as covariates. Differences
between groups were tested with χ2-tests and t-tests. All the statisti-
cal results were thresholded at p < .05, after Bonferroni correction
(0.05/number of comparisons).
Pearson's and Spearman's correlations were used to investigate
the associations among measurements. All p-values in correlation
analysis were adjusted with false discovery rate correction (FDR
<0.05) (Benjamini & Yekutieli, 2001).
The intrascanner variation (T0–T1) of each cortical diffusivity
measure was estimated using Cronbach's α. The intraclass correlation
coefficient (ICC) and its 95% confidence interval (95% CI) were used
to estimate reliability.
3 | RESULTS
3.1 | Demographics and clinical values
Table 1 summarizes the principal demographic and clinical characteris-
tics of all subjects included in the study.
In all cohorts, no significant difference was observed between
groups for age, years of formal education, or sex.
As expected, in all cohorts t-tests revealed lower MMSE
(p < .0001) and higher CDR score (p < .0001) in the AD groups.
3.2 | Structural MRI analysis
Volumetric brain values are summarized in Table 2.
In the Discovery cohort, AD patients showed a significantly lower
GM fraction than HC (t45 = 4.457; p < .0001). As expected, the AD
group showed a significantly lower Hipp Bil fr in (t45 = 4.695;
p < .0001). No significant between-group difference was found for
the WMHs fr.
In the Test cohort, AD patients showed a significantly lower GM
fraction (t50 = 5.831; p < .0001). and Hipp Bil fr (t50 = 6.934;
p < .0001) than HC. Moreover, the t-test analysis showed a signifi-
cantly higher WMHs fr in the AD group (t50 = 5.253; p < .010).
In the ATN cohort, the AD group showed a significantly lower
GM fraction (t48 = 7.872; p = .000.) and Hipp Bil fr (t48 = 7.691;
p = .000) compared to the HC group.
TABLE 3 Construct validity
Discovery cohort



















































































































































































































Note: Pearson's correlation among studied measures. “#” denotes Spearman's correlation.
*Significant after false discovery rate correction (FDR <0.05).
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3.3 | Cortical DTI analysis—results and validity
The results of the repeatability test, based on the comparisons
between baseline and the 3-month follow-up, revealed that all cortical
diffusivity measures (AngleR, MD, PerpPD, and ParlPD) had good to
excellent ICC (α = .89–.93).
Concerning reliability (interscanner variation), the differences
between HC and AD groups were tested in each cohort:
In the Discovery cohort, the GLM showed that just the diagnosis
had a significant overall effect (F4,42 = 11.048; p < .0001). No signifi-
cant effects of head movement or age were detected. Between
subjects, MD (F1,46 = 26.701; p < .0001), AngleR (F1,46 = 29.950;
p < .0001), PerpPD (F1,46 = 25.483; p < .0001), and ParlPD
(F1,46 = 16.014; p < .0001) were higher in AD.
In the Test cohort, the multivariate test showed a significant
effect of diagnosis (F4,45 = 16.435; p < .0001). No significant effects
of head movement or age were found. Between-subject effects rev-
ealed that MD (F1,51 = 19.313; p < .0001), AngleR (F1,51 = 50.088;
p < .0001) and PerpPD (F1,51 = 30.465; p < .0001) and ParlPD
(F1,51 = 11.055; p < .001) were higher in AD.
Finally, in the ATN cohort HC and AD were compared, controlling
for the effects of diagnosis, age, head movement and scanner. The
results showed significant effects of group diagnosis (F4,43 = 8.551;
p < .0001) and head movement (F4,43 = 16.992; p < .0001).
The tests of between-subject effects revealed that AngleR
(F1,49 = 29.658; p < .0001) and PerpPD (F1,49 = 8.419; p < .001) were
higher in AD. There was also an effect of head movement on MD
(F1,49 = 16.747; p < .0001), PerpPD (F1,49 = 8.678; p < .005), and ParlPD
(F1,49 = 13.899; p < .001). No other effects were found. All of the
results reported here remained significant after Bonferroni correction.
Construct validity was investigated using Pearson's correlation
coefficient to test the relationships between cortical diffusivity mea-
sures, structural and clinical variables. Several significant correlations
were found (see Table 3 for more details).
Concerning the relationships among the cortical diffusivity analy-
sis measures and the other biomarkers included in the ATN
F IGURE 1 Correlations between cortical diffusion (AngleR and PerPD) and PET SUVR values (AV45 and AV1451). The graphs show
significant positive correlations between a) AngleR and AV45 SUVR values (r = .616; p = .000, pFDR = 0), (b) AngleR and AV1451 SUVR (r = .373;
p = .015, pFDR = .045), (d) PerpPD and AV1451 SUVR (r = .351; p = .023 pFDR = .046). The correlation between (c) PerpPD and AV45 SUVR
values did not survive FDR correction (r = .307; p = .048, pFDR = .072)


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TORSO ET AL. 7
framework (concurrent validity), correlation analyses revealed signifi-
cant positive correlations between AngleR and AV45 SUVR values
(r = .616; p = .000, pFDR = 0), AngleR and AV1451 SUVR (r = .373;
p = .015, pFDR = .045) PerpPD and AV1451 SUVR (r = .351; p = .023
pFDR = .046). The correlation between PerpPD and AV45 SUVR
values did not survive FDR correction (r = .307; p = .048, pFDR = .072).
No significant correlations between ParlPD and PET values were
found (Figure 1).
3.4 | Diagnostic accuracy (classification
effectiveness in comparison to other methods)
The ability of each measure to correctly classify AD and non-AD sub-
jects was assessed using the receiver operating characteristics (ROC)
curve. Table 4 and Figure 2 show the principal measures of diagnostic
reliability of cortical diffusivity measures. For each group, ROC analy-
sis was performed on the structural volume measure (GM fr) and dif-
fusion cortical indices (MD, AngleR, PerpPD, and ParlPD).
In the Discovery cohort, as expected, GM fr provided good group
discrimination, having AUC = 0.816.
Among diffusion cortical values, AngleR was the best between-
group discriminator, having an AUC = 0.887, followed by MD
(AUC = 0.862) and PerpPD (AUC = 0.850). The AngleR cutoff, desig-
nated the “best” point of the ROC curve was 0.981 θrad.
Therefore, additional statistics were generated for AngleR: Likeli-
hood ratio values (LR− = 0.14; LR+ = 6.7) revealing that individuals
with AngleR values greater than 0.981 θrad (Figure 3) had an
increased probability of disease compared to individuals with lower
AngleR values. Moreover, using the cut-off of 0.981 θrad all
F IGURE 2 Discriminations using the AngleR cutoff corresponding to the “best” point in the ROC curves
F IGURE 3 This figure shows that no single marker, including MMSE score, is adequate for identifying patients with a clinical diagnosis of
Alzheimer's Disease. The x axis shows categories with increasing number of positive markers. In general, subjects with only one positive marker
(toward the left side) are healthy controls (blue) and indicate false positives for the individual markers which report a positive. Whereas, with
increasing combined marker positivity, more subjects are found to be AD patients (red) and on the right side of the graph the red points indicate
false negatives for those markers which report a negative. Interestingly, a few AD patients were Amyloid negative subjects with above threshold
MMSE, but were positive on the other markers. (Note that the ADNI3 protocol defined AD subjects with MMSE within the range 20–24,
however, some subjects presented here were carried over from the earlier ADNI data sets within which the original criteria defined AD with
MMSE 20–26)
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individuals were classified with an accuracy of 87% and a J of 0.74,
NPV (87%) and PPV (88%).
In the Test cohort (similar to the Discovery cohort results), GM fr
provided very good group discrimination having an AUC = 0.870.
AngleR obtained the best between-group discrimination, having an
AUC = 0.931, followed by PerpPD (AUC = 0.903) and MD
(AUC = 0.858). The AngleR cut-off point determined that the “best”
point of the ROC curve was 0.983 θrad.
For AngleR, the likelihood ratio values (LR− = 0.15; LR+ = 20.5)
revealed that individuals with AngleR values greater than 0.983 θrad
(Figure 3) had an increased probability of disease compared to individ-
uals with lower AngleR values. By using an AngleR threshold of 0.983
θrad, all individuals were classified with an accuracy of 90%, J 0.815,
NPV (85%), and PPV (96%).
Finally, we estimated the discrimination power for each measure
in the ATN (ADNI 3) cohort. This analysis confirmed the results of the
“Test” and “Discovery” cohorts, showing a good discrimination power
of GM fr, with an AUC = 0.798. Among diffusion cortical values, the
analysis revealed that AngleR gave the best between-group discrimi-
nation, having an AUC = 0.896, followed by PerpPD (AUC = 0.666)
and MD (AUC = 0.629). AngleR had likelihood ratio values of (LR-
= 0.05; LR+ = 3.4) revealing that individuals with AngleR values
greater than 0.968 θrad (Figure 3) had an increased probability of dis-
ease compared to individuals with lower AngleR values. Using a
threshold for AngleR of 0.968 θrad, all individuals were classified with
an accuracy of 84% and a J of 0.68. This strong classification power of
AngleR was also confirmed by NPV (95%) and PPV (77%).
4 | CONCLUSION
Previous histological studies have revealed that AD results in progres-
sive damage to minicolumn organization (Chance et al., 2011; van
Veluw et al., 2012). This process, led by neurite loss and then neuronal
death, causes progressive damage to the normal organization of corti-
cal cells in columns, producing an alteration of cortical geometric
properties (Chance et al., 2011; van Veluw et al., 2012). Therefore, we
considered the alteration of such geometric properties as a biomarker,
potentially measurable using a tailored, novel DTI analysis method.
Although DTI is a relatively crude tool for analyzing diffusion MRI, it
can be useful for exploring markers of disease and has been shown to
relate to the underling cytoarchitecture (McKavanagh et al., 2019).
With respect to the main aims of the study, the results suggested
that the cortical diffusivity analysis did detect group differences accu-
rately and satisfy validity requirements overall.
The validity of a test is based on its ability to measure reliably
(Repeatability and Reliability) for the group of variables that it is
designed to measure (Construct Validity) and to correctly distinguish
subjects with the disease from healthy subjects (Diagnostic Accuracy)
in accordance with other pre-existing scores (Concurrent validity). The
validity of the method was tested here, to determine the possibility of
generalizing the results obtained, by investigating repeatability, reli-
ability, construct validity, and concurrent validity.
The intrascanner variation showed that the scores obtained at
the two timepoints were strongly correlated and significantly consis-
tent, with the two timepoints being much closer to each other com-
pared to the difference between subjects, indicating a good
repeatability. It must be acknowledged that there was a gap of a few
weeks between time points.
The interscanner variation, assessed by applying the cortical diffu-
sivity analysis to images from groups of healthy and AD subjects
acquired on different scanners, revealed a good reliability of the corti-
cal diffusivity analysis measures. The results obtained in all cohorts
showed that subjects with AD had significantly higher values for
AngleR measurements suggesting that the results were not related to
the characteristics of a single sample, scanner, or operator. Further
evidence from application to data across scanners came from the mul-
ticentre ATN cohort, which was an open source image dataset (ADNI
3). Although the images were from different scanners, the novel diffu-
sion measures (in particular AngleR), remained sensitive to group dif-
ferences, whereas other measures appeared susceptible to
interscanner differences.
Interscanner variability represents a significant challenge in diffu-
sion imaging. Previous studies have shown that diffusion measures
can be influenced by many factors, such as acquisition protocols, anal-
ysis approaches, b-value, signal-to-noise ratio, image resolution, scan-
ner model, co-registration methods, and reslicing (Bisdas, Bohning,
Bešenski, Nicholas, & Rumboldt, 2008; Correia, Carpenter, &
Williams, 2009; Papinutto, Maule, & Jovicich, 2013; Takao, Hayashi,
Kabasawa, & Ohtomo, 2012; Zhu et al., 2011). In order to limit the
number of sources of confounding variation, the present study con-
trolled for some differences by using scans acquired with comparable
protocols on scanners from the same manufacturer (Siemens). To fur-
ther generalize the diffusion analysis approach presented here, addi-
tional investigations combined with harmonization methods are
recommended.
The cortical diffusion analysis appeared to have good Construct
Validity (Table 3) as confirmed by significant correlations between the
novel diffusion measures and other commonly used measures of neu-
rodegeneration (e.g., MMSE, Hipp bil fr, and GM_fr). AngleR values
were also correlated with AV45 PET values, while PerpPD values
were correlated with AV45 and AV1451 PET values. These results
suggested a good relationship between the cortical diffusivity analysis
measures and pre-existing measures (Concurrent Validity), and a con-
sistency among AD biomarkers.
The potential diagnostic accuracy of the McKavanagh et al.
Method was tested using ROC curve analysis and by calculating vari-
ous predictive indices (PPV, NPV, J, LR+, and LR−) estimating discrimi-
native power. Taken together, the results showed that AngleR had the
highest AUC and Accuracy among the measures considered in the
analyses.
In addition, by comparing the Accuracy values for each measure
in the ATN cohort, with AV45 and AV1451 PET, the discriminative
power of AngleR was able to classify patients at a level similar to sev-
eral conventional measures that are widely used in clinical practice
(Jack Jr et al., 2018).
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The structural MRI results are consistent with previous studies
(e.g., Cuingnet et al., 2011), but the amyloid PET AUC differed slightly
from some other studies (e.g., Palmqvist et al., 2015). Variation in PET
amyloid results across studies could be due to sample size differences
and/or selection of target regions. Both factors can produce signifi-
cant changes in AUCs. The present study used the main whole brain
amyloid value provided in the ADNI dataset.
There is, potentially, additive value in using a range of methods
that provide complementary information and can provide increasing
confidence of patient classification.
It is worth noting that these results are based on the diagnosis of
moderate–severe AD, in order to explore the discriminatory power of
the method on a well-characterized sample with clear diagnostic indi-
ces available. This enabled evaluation of the concurrent validity of the
method. Of course, the ultimate goal is to move beyond the detection
of moderate–severe AD, which offers limited insight for clinical prac-
tice, toward a preliminary validation of a method that could enhance
quantification of the “N” component of the ATN framework (Jack Jr
et al., 2018) earlier in the disease. This could have applications in dif-
ferential diagnosis (Torso, Ahmed, et al., 2020; Torso, Bozzali,
et al., 2020)) with respect to other forms of dementia and ideally in
early diagnosis for detecting early changes in cortical architecture. As
shown by previous studies (Dubois et al., 2016), the predictive power
of conventional biomarkers in the preclinical AD population requires
improvement, creating a need for new biomarkers and instruments
capable of more effectively detecting preclinical AD.
The objective of the ATN criteria is to separate the biomarker
profile of the disease that represents the underlying pathology from
the clinical diagnosis of symptoms, which can often be mimicked in
other forms of disease. This raises the prospect of a potential discon-
nect between the biomarker and the clinical definitions and evidence
of this can be seen in Figure 3, where there are a number of HC indi-
viduals who may be in the preclinical stage of AD. It is also possible
that “AD” individuals who are amyloid negative should be considered
atypical. Nonetheless, the findings of the present study are broadly
supportive of the principle of ATN criteria.
5 | LIMITATIONS
This study has some limitations: the study included a relatively small num-
ber in each cohort for the purpose of validation, further studies with
larger cohorts would be recommended to fully generalize the findings. An
additional limitation concerned interscanner reliability. In an ideal study
the same individual subjects would be scanned using different acquisi-
tions and on different scanners. This is very difficult to realize in practice,
especially for subjects with AD, where a repeated acquisition would be
very taxing and stressful for the patient, difficult to justify from an ethical
point of view, and challenging for recruitment. All the data in the present
study were drawn from existing datasets and in that respect at least, they
do not represent a cohort specially optimized for our analysis.
In summary, the present study attempts to step towards building a
bridge between previously characterized histopathological markers of
dementia and current MRI methods. Further investigation on additional
datasets will be needed, but this cortical DTI measurement, in addition to
other methods already in use, appears to have the potential to contribute to
improving diagnostic classification for Alzheimer's Disease. Such methods
could form part of a repertoire of assessments to assist early diagnosis of
the disease and differential diagnosis from other forms of dementia.
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